Tau pathology was analyzed by immunohistochemistry, first for phospho-epitope pT231 defined by antibody AT180, because it is one of the earliest markers for tauopathy in AD, and widely used as clinical biomarker in CSF for early diagnosis [62]–[64]. This evidence concerns the gene MAPT and tauopathy.